The appearance of so-called bird flu remedies which have hit the market in the U.S. have prompted the Food and Drug Administration (FDA) to issue warnings to nine companies.The companies have now
Patients with advanced colorectal cancer have new hope for a longer life. The Food and Drug Administration recently approved the drug
Researchers at the University of British Columbia Centre for Health Services and Policy Research have developed a comprehensive portrait of pharmaceutical spending in Canada -- more than $20 billion by the
King Pharmaceuticals, Inc. has reported the receipt by its Meridian Technologies subsidiary of a letter from
Advancements in biotechnology have culminated in its integration with semiconductor technologies suc
GW Pharmaceuticals and Bayer HealthCare, Pharmaceuticals Division - Canada have announced that GW has submitted a New Drug Subm
According to an FDA advisory panel, studies show that an experimental vaccine to prevent shingles can cut the rate of infection by about half in people 60 and older and help curb related pain.But
French drug company Sanofi Pasteur says early stage trials of an experimental vaccine against H5N1 bird flu have shown it provides a good immune response in humans and is safe.Sanofi Pas
Custom officers in the U.S. have seized 51 shipments of a fake anti-bird flu drug.The counterfeit medication had been shipped from Asia to an airmail facility in San Francisco, and Customs and Border Protection officers say each box contained 1
GenoMed, Inc. a Next Generation Disease Management company that uses its expertise in genomics to improve clinical outcomes in as many species as possible, announced today that two non-profit groups which care for w
The FDA's Fast Track programs are designed to facilitate the development and expedite review of drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. With Fast Track designation, there may be more frequent interactions with the FDA during the development of a product and eventually a company may be eligible to file a U.S. biologics license application (BLA) on a rolling basis as data becomes available. This permits the FDA to review a filing as it is received, rather than waiting for the entire document prior to commencing the review process. Due to the nature of these types of products, BLAs filed with Fast Track status are generally eligible for priority review, which could decrease the typical review period.
Biomira submitted a Fast Track application to the FDA, which included encouraging results from a controlled, randomized Phase IIb study in Stage IIIB and IV NSCLC patients. Results from the Phase IIb study will be presented at the European Society of Medical Oncology meeting (ESMO) to be held in Vienna, Austria, on November 1.
A recent letter received from the FDA stated, "We have reviewed your request and concluded that it meets the criteria for the Fast Track designation. Therefore, we are designating as a Fast Track Drug Product development program the investigation of Liposomal Vaccine in the extension of survival among patients with unresectable stage 3a and locoregional stage 3b non-small cell lung cancer following first line chemotherapy. We look forward to working with you to expedite the development and review of this promising proposed use of the product."
"Fast Track designation for L-BLP25 for the treatment of these patients is an important step in the development of this product candidate and may help us bring this potentially promising drug to patients more quickly," said Alex McPherson, MD, PhD, President and CEO of Biomira. "This is a significant milestone for the Company, highlighting the importance of product candidates such as L-BLP25 to one day address a sizeable unmet need in this patient population. We believe our vaccine will be able to provide a new treatment option for men and women with NSCLC that has the potential to both extend and improve the quality of their lives."
L-BLP25 is a synthetic MUC1 peptide vaccine, designed to induce an immune response to cancer cells. L-BLP25 incorporates a 25-amino acid sequence of the MUC1 cancer mucin, encapsulated in a liposomal delivery system. The liposome enhances recognition of the cancer antigen by the immune system and facilitates better delivery.
Biomira and Merck KGaA continue to explore opportunities for early registration for this product candidate with other regulatory agencies. Plans are also underway for a confirmatory Phase III study.
http://www.biomira.com/, http://www.merck.de/